Selective serotonin reuptake inhibitor discontinuation syndrome: A review


Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed in the treatment of depression and anxiety, as well as obsessive-compulsive, eating, and impulse-control disorders. Paralleling their widespread use has been an increase in adverse-effect reports not noted during short-term efficacy studies. Significant among these adverse effects is SSRI discontinuation syndrome, which follows the interruption of extended treatment or a reduction in drug dosage and entails somatic and psychological symptoms. These self-limiting symptoms resolve on reintroduction of the drug and cannot be explained as a remanifestation of the original disorder. To facilitate proper diagnosis and avoid unnecessary therapeutic or diagnostic interventions, all physicians who prescribe SSRIs should become familiar with these symptoms. The most appropriate approach to therapy for discontinuation syndrome involves educating patients and reassuring them that this is a reversible condition, reinstating the original SSRI, and further slowing the rate of tapering.

This is a preview of subscription content, log in to check access.


  1. 1.

    Haddad P. The SSRI discontinuation syndrome.J Psychopharmacol. 1998;2:305–313.

    Article  Google Scholar 

  2. 2.

    Preskorn SH.Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. Professional Communications Inc; 1996.

  3. 3.

    Stahl MMS, Lindquist M, Peterson M, et al. Withdrawal reactions with selective serotonin reuptake inhibitors as reported to the WHO system.Eur J Clin Pharmacol. 1997;53:163–169.

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Price JS, Waller PC, Wood SM, Mackay AV. A comparison of post-marketing safety of four selective re-uptake inhibitors including the investigation of symptoms occurring on withdrawal.Br J Clin Pharmacol. 1996;42:757–763.

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder.J Clin Psychiatry. 1993;54:146–149.

    PubMed  CAS  Google Scholar 

  6. 6.

    Black K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.J Psychiatry Neurosci. 2000;25:255–261.

    PubMed  CAS  Google Scholar 

  7. 7.

    Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance.Int Clin Psychopharmacol. 2000;15:305–318.

    PubMed  CAS  Google Scholar 

  8. 8.

    Haddad P, Lejoyeux M, Young A. Antidepressant discontinuation reactions.BMJ. 1998;316: 1105–1106.

    PubMed  CAS  Google Scholar 

  9. 9.

    Lejoyeux M, Ades J. Antidepressant discontinuation: a review of the literature.J Clin Psychiatry. 1997;58(suppl 7):11–16.

    PubMed  CAS  Google Scholar 

  10. 10.

    Lane RM. Withdrawal symptoms after discontinuation of selective serotonin reuptake inhibitors.J Serotonin Res. 1996;3:75–83.

    CAS  Google Scholar 

  11. 11.

    Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.Biol Psychiatry. 1998;44:77–87.

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review.J Clin Psychiatry. 1997;58:291–297.

    PubMed  CAS  Google Scholar 

  13. 13.

    Skaehill PA, Welch EB. SSRI withdrawal syndrome.Consult Pharm. 1997;12:1112–1118.

    Google Scholar 

  14. 14.

    Benazzi F. Mirtazapine withdrawal symptoms.Can J Psychiatry. 1998;43:525.

    Google Scholar 

  15. 15.

    Boyd IW. Venlafaxine withdrawal reactions.Med J Aust. 1998;169:91–92.

    PubMed  CAS  Google Scholar 

  16. 16.

    Diler RS, Tamam L, Avci A. Withdrawal symptoms associated with paroxetine discontinuation in a 9-year old boy.J Clin Psychopharmacol. 2000;20:586–587.

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Fava GA, Grandi S. Withdrawal syndromes after paroxetine and sertraline discontinuation.J Clin Psychopharmacol. 1995;15:374–375.

    PubMed  Article  CAS  Google Scholar 

  18. 18.

    Frost L, Lal S. Shock-like sensations after discontinuation of selective reuptake inhibitors.Am J Psychiatry. 1995;152:180.

    Google Scholar 

  19. 19.

    Green B. Persistent adverse neurological effects (PANES) following SSRI discontinuation. Psychiatry On-line, 2000. Available at: Accessed November 2001.

  20. 20.

    Koopowitz LF, Berk M. Paroxetine induced withdrawal effects.Hum Psychopharmacol. 1995; 10:147–148.

    Article  Google Scholar 

  21. 21.

    Lauber C. Nefazodone withdrawal symptoms.Can J Psychiatry. 1999;44:285–286.

    PubMed  CAS  Google Scholar 

  22. 22.

    Louie AK, Lannon RA, Ajari LJ. Withdrawal reactions after sertraline discontinuation.Am J Psychiatry. 1994;151:450–451.

    PubMed  CAS  Google Scholar 

  23. 23.

    Stoukides JA, Stoukides CA. Extrapyramidal symptoms upon discontinuation of fluoxetine.Am J Psychiatry. 1991;148:1263.

    PubMed  CAS  Google Scholar 

  24. 24.

    Szabadi E. Fluvoxamine withdrawal syndrome.Br J Psychiatry. 1992;160:283–284.

    PubMed  CAS  Google Scholar 

  25. 25.

    Rosenstock HA. Sertraline withdrawal in 2 brothers: a case report.Int Clin Psychopharmacol. 1996;11:58–59.

    PubMed  Article  CAS  Google Scholar 

  26. 26.

    Coupland N, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal.J Clin Psychopharmacol. 1996;16:356–362.

    PubMed  Article  CAS  Google Scholar 

  27. 27.

    Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment.Br J Psychiatry. 2000;176:363–368.

    PubMed  Article  CAS  Google Scholar 

  28. 28.

    Olver JS, Burrows GD, Norman TR. Discontinuation syndromes with selective serotonin reuptake inhibitors. Are there clinically relevant differences?CNS Drugs. 1999;12:171–177.

    Article  CAS  Google Scholar 

  29. 29.

    Mann AM, MacPherson AS. Clinical experience with imipramine in the treatment of depression.CMAJ. 1959;4:38–47.

    CAS  Google Scholar 

  30. 30.

    Cooper GL. The safety of fluoxetine: an update.Br J Psychiatry. 1988;153(suppl 3):77–86.

    Google Scholar 

  31. 31.

    Bryois C, Rubin C, Voirol P, Kosel M, Baumann P. Withdrawal symptoms after discontinuation of a citalopram treatment: a prospective study.Eur Neuropsychopharmacol. 1997;7(suppl 2):S142.

    Article  Google Scholar 

  32. 32.

    Dilsaver SC, Greden JF, Snider RM. Antidepressant withdrawal syndromes: phenomenology and physiopathology.Int Clin Psychopharmacol. 1987;2:11–19.

    Article  Google Scholar 

  33. 33.

    Schatzberg AF, Haddad P, Kaplan EM, et al. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition.J Clin Psychiatry. 1997;58(suppl 7):5–10.

    PubMed  CAS  Google Scholar 

  34. 34.

    Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn.J Clin Psychopharmacol. 1995;15:417–420.

    PubMed  Article  CAS  Google Scholar 

  35. 35.

    Kent LSW, Laidlaw JDD. Suspected congenital sertraline dependence.Br J Psychiatry. 1995;167: 412–413.

    PubMed  CAS  Article  Google Scholar 

  36. 36.

    Spencer MJ. Fluoxetine hydrochloride toxicity in neonates.Pediatrics. 1993;92:721–722.

    PubMed  CAS  Google Scholar 

  37. 37.

    Schatzberg AF, Haddad P, Kaplan EM, et al. Possible biological mechanisms of serotonin reuptake inhibitor discontinuation syndrome.J Clin Psychiatry. 1997;58(suppl 7):23–27.

    PubMed  CAS  Google Scholar 

  38. 38.

    Rosenbaum JF, Zajecka J. Clinical management of antidepressant discontinuation.J Clin Psychiatry. 1997;58(suppl 7):37–40.

    PubMed  CAS  Google Scholar 

  39. 39.

    Kaplan EM. Antidepressant noncompliance as a factor in the discontinuation symptoms.J Clin Psychiatry. 1997;58(suppl 7):31–36.

    PubMed  Google Scholar 

  40. 40.

    Young AH, Currie A. Physician knowledge of antidepressant withdrawal effects: a survey.J Clin Psychiatry. 1997;58(suppl 7):28–30.

    PubMed  Google Scholar 

  41. 41.

    Debattista C, Schatzberg AF. Physical symptoms associated with paroxetine withdrawal.Am J Psychiatry. 1995;152:1234–1235.

    Google Scholar 

  42. 42.

    Raby WN. Treatment of venlafaxine discontinuation symptoms with ondansetron.J Clin Psychiatry. 1998;59:621–622.

    PubMed  CAS  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Lut Tamam M.D..

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Tamam, L., Ozpoyraz, N. Selective serotonin reuptake inhibitor discontinuation syndrome: A review. Adv Therapy 19, 17–26 (2002).

Download citation


  • selective serotonin reuptake inhibitors
  • antidepressants
  • discontinuation syndrome
  • adverse effects